Skip to main content
CRS 2025 Annual Meeting & Exposition Main banner
Final Program


CRS Abstract Guide
Rate Poster

Gene Delivery and Gene Editing (Focus Group - GDGE)

(167) Surf-LNPs: Lung surfactant-doped lipid nanoparticles for enhanced RNA pulmonary delivery

Introduction:

Wide clinical deployment of Lipid nanoparticle (LNP)-encapsulated mRNA Covid-19 vaccines posed LNPs as RNA delivery gold standard[1] . Yet therapeutic rather than vaccine applications of LNPs-RNA requires modifications to limit LNP’s immunogenicity at mucosal surfaces like the lungs[2]. protein replacement therapies require enhancing protein expression (1000X folds) [3]. Given structural similarity between commercially available lung surfactant (Proactant-α) and helper lipid component (DSPC) of LNPs we attempted replacing DSPC with Proactant-α and observed the impact on LNP behavior in vitro.

Learning Objectives:

  • Full helper lipid replacement with Proactant-α does not impact LNP’s colloidal properties.
  • Proactant-α improves in vitro transfection efficiency of Surf-LNPs relative to a classical LNPs.
Gregg Duncan – Associate Professor, Fischell Department of Bioengineering, University of Maryland, College Park